The Bull Rankings scorecard — our quality-growth score is 53.8 / 100, built from three pillars scored 0–100: Quality 70, Growth 49, Value 45 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 10% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Kenvue is a high-quality compounder with a built-in moat in everyday health categories, yet the stock isn’t cheap enough to justify the growth it’s priced for. Our model gives it a 53.8/100 quality-growth score, with the strongest pillar being Quality at 70—a score earned on the back of a 15.7% return on equity and a 10.8% profit margin as of the quarter ended 2026-06-28. That’s the good news. The bad news is that the weakest pillar, Value at 45, tells the rest of the story: the P/E sits at 22.6, on the expensive side of its peers. The market isn’t rewarding this franchise for its durability; it’s assuming free cash flow grows 10% next year, slowing to 3% a year by year ten, a starting rate that outpaces the 1.8% revenue growth reported in the same period. That’s optimism priced in, and it leaves little room for error.
What the business actually is
Kenvue sells products people reach for when they’re sick, stressed, or simply trying to look and feel better. In the Self Care segment, it dominates categories like cough, cold, and allergy remedies, pain care, digestive health, and smoking cessation—think Tylenol, Zyrtec, or Nicorette. Skin Health and Beauty covers face and body care, hair, sun protection, and cosmetics, while Essential Health includes oral care, baby care, women’s health, wound care, and vitamins. These aren’t luxuries; they’re staples, which means demand persists even when budgets tighten. The company’s scale across North America, Europe, and emerging markets gives it pricing power and shelf space advantages that smaller rivals can’t match quickly.
Why it can (or can't) keep compounding
The durability case rests on two pillars: returns that keep coming and brands that refuse to fade. A 15.7% return on equity isn’t just high—it’s sticky, the kind of number that suggests pricing power and efficient capital use. The 10.8% profit margin reinforces this, proving the business can turn every dollar of revenue into nearly eleven cents of pure profit as of the quarter ended 2026-06-28. The moat isn’t in patents or tech; it’s in the trust built over decades in categories where switching costs are low but habit is high. A competitor can copy a formula, but replicating the distribution network, the shelf placement, and the consumer trust behind Tylenol or Band-Aid takes years. That’s why the Quality pillar sits at 70—this isn’t a flash in the pan.
The valuation question
The price already assumes the company can outgrow its own recent performance. Our model’s reverse DCF says today’s $19.17 share price implies 10% free-cash-flow growth (in year one, slowing to 3% a year by year ten), a rate that far outstrips the 1.8% revenue growth reported for the year. The P/E of 22.6 doesn’t scream overvaluation on its own, but when paired with stagnant top-line growth, it suggests the market is pricing in margin expansion, a growth rebound, or both. The analyst consensus target of $19.50, with a range of $18 to $23, is essentially a shrug—no one is betting on a big move up or down. That’s not a ringing endorsement. The stock’s 0.43 beta means it has tended to move less than the market in both directions. The question isn’t whether Kenvue is a good business. It’s whether it’s a good stock at this price.
The bear case
The skeptic’s argument is simple: growth has stalled. Revenue grew just 1.8% in the year ended 2026-06-28, yet the market is pricing in a free-cash-flow machine that grows at more than five times that pace. The debt-to-equity ratio of 0.82 isn’t alarming, but it’s not trivial either for a company that’s supposed to be a low-risk compounder. The weakest pillar in our model, Value at 45, isn’t just a label—it’s a warning that the stock’s premium isn’t justified by the fundamentals. If revenue growth stays sluggish and margins slip even slightly, the 10% implied growth in the reverse DCF will look like fantasy. That’s the bear case in one sentence: the market is pricing in a recovery that isn’t happening.
What would change our mind
Three things would flip the thesis. First, revenue growth accelerates above 3%—a clear sign the Self Care and Skin Health segments are gaining share. Second, free-cash-flow growth sustains above 12% for two consecutive years, proving the growth the price implies isn’t a fluke. Third, the Value pillar rises above 55, which would mean the price has come down to a level the fundamentals support. Until then, Kenvue remains a high-quality business trading at a premium it hasn’t earned. The moat is real. The growth isn’t. That’s the tension.